Behavioral phenotyping of cancer pain in domesticated cats with naturally occurring squamous cell carcinoma of the tongue: initial validation studies provide evidence for regional and widespread algoplasticity

Yen-Hao Erik Lai¹,², B. Duncan X. Lascelles¹,²,³ and Michael W. Nolan¹,²,³

¹ Comparative Medicine Institute, North Carolina State University, Raleigh, NC, United States of America
² Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, United States of America
³ Comparative Pain Research and Education Center, North Carolina State University, Raleigh, NC, United States of America

ABSTRACT

Feline oral squamous cell carcinoma (FOSCC) is a common and naturally occurring condition that recapitulates many features of human head and neck cancer (HNC). In both species, there is need for improved strategies to reduce pain caused by HNC and its treatment. Research to benefit both species could be conducted using pet cats as a comparative model, but this prospect is limited by lack of validated methods for quantifying FOSCC-associated pain. A prospective non-randomized pilot study was performed for initial validation of: (1) a pet owner administered quality of life questionnaire and visual assessment scoring tool (FORQ/CLIENT); (2) a clinician assessment questionnaire (UFEPS/VET); (3) electronic von Frey testing [EVF]; and (4) Cochet-Bonnet (COBO) aesthesiometry. To assess intra-rater reliability, discriminatory ability, and responsiveness of each assay, 6 cats with sublingual SCC and 16 healthy control cats were enrolled. The intra-rater reliability was moderate-to-good for the clinical metrology instruments and EVF (intraclass correlation coefficient [ICC] ≥ 0.68), but poor for COBO (ICC = 0.21). FORQ/CLIENT scores were higher (worse quality of life) in FOSCC cats vs healthy controls. The internal reliability of FORQ/CLIENT scoring was high (Cronbach α = 0.92); sensitivity and specificity were excellent (100% when using cut-offs determined using receiver operating characteristic [ROC] curves). For the FORQ/CLIENT, there was strong and inverse correlation between scores from the questions and visual assessment (r = −0.77, r² = 0.6, P < 0.0001). For the UFEPS/VET, Cronbach’s α was 0.74 (high reliability). Sensitivity and specificity were 100% and 94%, respectively, when using a cut-off score (3.5) based on ROC curves (Youden index of 0.94). Total UFEPS/VET scores were positively correlated with FORQ/CLIENT scores (r² = 0.72, P < 0.0001). Sensitivity of EVF and COBO ranged from 83 to 100% and specificity ranged from 56 to 94%. Cats with cancer were more sensitive around the face (lower response thresholds) and on the cornea (longer filament lengths) than control animals (P < 0.03). Reduced pressure response thresholds were also observed at a distant site (P = 0.0002) in cancer cats.
Giving buprenorphine, EVF pressure response thresholds increased ($P = 0.04$) near the mandible of cats with OSCC; the length of filament required to elicit a response in the COBO assay also improved (shortened; $P = 0.017$). Based on these preliminary assessments, the assays described herein had reasonable inter-rater reliability, and they were able to both discriminate between cats with and without oral cancer, and respond in a predictable manner to analgesic therapy. In cats with tongue cancer, there was evidence for regional peripheral sensitization, and widespread somatosensory sensitization. These results provide a basis for multi-dimensional assessments of pain and sensitivity in cats with oral SCC.

**Subjects** Animal Behavior, Neuroscience, Veterinary Medicine, Zoology, Oncology  
**Keywords** Comparative oncology, Comparative pain research, Animal models, Translational research, Feline

### INTRODUCTION

Pain is a common symptom of human head and neck cancer (HNC). Approximately three in five HNC patients report pain (Macfarlane et al., 2012). Effective pain relief is not achieved with currently available analgesics (Portenoy, 2011; Ripamonti et al., 2012), and the commonly used opioids are addictive, cause significant side effects, and have abuse potential (McNicol et al., 2003). The need for improved HNC analgesics is underscored by the fact that each year, HNC is diagnosed in more than 650,000 people worldwide (Bray et al., 2018). Unfortunately, translational pain research based solely on induced rodent models and then human clinical trials is not efficiently producing new analgesic therapies (Rice et al., 2008; Mogil, 2009). Using an animal model in which the disease is naturally occurring and similar to the human condition may be more predictive of human clinical efficacy (Lascelles & Flecknell, 2010; Klinek et al., 2017; Lascelles et al., 2019). Feline oral SCC (FOSCC) is one of the most common cancers in cats. While FOSCC is not reported to be virally-induced, its biological activity is quite similar to human papilloma virus-negative head and neck SCC (HPV negative HNSCC) in that both are locally aggressive cancers for which: (1) therapeutic resistance is common, and (2) local tumor progression tends to be a common cause for early disease-specific morbidity and mortality (Bilgic et al., 2015).

While the discomfort caused by FOSCC has not been well-studied, veterinary oncologists anecdotally and widely recognize this disease as being a source of considerable pain, which appears to be clinically similar to that pain which is experienced by people with HNC. Thus, FOSCC could be a useful translational, naturally occurring model of oral cancer pain. However, to be a useful model, robust outcome measures are needed, and currently, none have been developed or described. To address that gap, the goal of this study was to develop and assess methods to measure FOSCC-associated pain. To ensure the greatest translational value, it is important that the outcome measures developed for FOSCC-associated pain closely mimic those used in human medicine. We therefore evaluated three different types of pain and/or sensitivity assessment methods: client questionnaires, clinician-based pain scales and quantitative sensory testing (QST).
Several methods and instruments have been used in human HNC patients for measuring pain, including QOL questionnaires (Niv & Kreitler, 2001; Infante-Cossio et al., 2009). In veterinary patients, pet owner-reported questionnaires have been used to measure QOL and pain-associated behaviors in canine cancer patients (Yazbek & Fantoni, 2005; Lynch et al., 2011; Giuffrida, Farrar & Brown, 2017; Reid, Nolan & Scott, 2018). However, none of these tools were developed specifically for orofacial cancers, or cats. In this study, an owner-reported QOL questionnaire, called the Canine Owner-Reported QOL Questionnaire (CORQ), originally designed to assess QOL in dogs with cancer was used as a guide to construct a tool for measuring QOL in relation to FOSCC, and termed the FORQ—Feline Oral Cancer Owner-Reported QOL Questionnaire (Giuffrida et al., 2018); for ease of reading, it is hereafter referred to (in-text) as the FORQ/CLIENT, to provide readers with a quick reminder that this is the client (pet owner) questionnaire.

Attending physician assessments have been used in human pain medicine to complement patient and caregiver reports; a similar approach can be used in cats, with assessments performed by attending veterinarians (Hadjistavropoulos et al., 1997; Zwakhalen et al., 2004; Kunz et al., 2007). Clinician-completed pain scales have been developed for acute pain in cats (Brondani, Luna & Padovani, 2011; Brondani et al., 2013; Calvo et al., 2014; Reid et al., 2017); instruments have also been developed for evaluating chronic osteoarthritis pain in cats (Lascelles et al., 2007; Benito et al., 2013a; Benito et al., 2013b; Gruen et al., 2015; Klinck et al., 2018b; Klinck et al., 2018a) but none have been developed for the assessment of long-standing orofacial cancer pain. Recently, Stathopoulos et al. (2018) used a modified multifactorial composite pain scale (MCPS) from the Universidade Estadual Paulista Campus de Botucatu (UNESP-Botucatu) to identify the analgesic effect of buprenorphine in cats with gingivostomatitis. Based on their positive results, we felt there was a reasonable chance that a similarly modified scale might also provide a robust measure of feline oral cancer pain; thus, additional modifications to the modified UNESP-Botucatu MCPS scale were applied and studied here; in this manuscript, it is referred to hereafter as the UFEPS/VET to reflect the origin of the scale (see literature citation, where the UNESP-Botucatu MCPS is referred to as the UFEPS) and to quickly orient readers to the fact that this is the questionnaire being administered by the veterinary team (vs. the FORQ/CLIENT, which is the pet owner administered tool) (Belli et al., 2021).

In addition to use of clinical metrology instruments such as the UFEPS, complementary information can be gathered through QST. This is potentially useful because pain affects multiple dimensions, and not necessarily all equally (Lascelles et al., 2019). Mechanical and thermal QST represent methodologies that have been used to measure local and distant sensitivity that occurs in humans, and in rodent models (Matos et al., 2011; Zaslansky & Yarnitsky, 1998; Ye et al., 2017). Such methodologies have also been used in dogs with cancer (Monteiro et al., 2018). Electronic von Frey (EVF) and Cochet-Bonnet (COBO) aesthesiometers are examples of mechanical QST (mQST) instruments that have been used for testing cutaneous and/or joint pressure sensitivity, and corneal sensitivity in both dogs and cats (Chan-Ling, 1989; Barrett, Scagliotti & Merideth, 1991; Blocker & Van Der Woerd, 2001; Briley et al., 2014; Machin, Kato & Adami, 2019). To date, these methods have not been used to assess pain/sensitivity in cats with oral cancer.
A combination of all of these tools formed the basis for the present pilot study, which was performed to begin: (1) validating tools for measuring FOSCC associated pain, and (2) defining various features of oral cancer pain in cats. We hypothesized that it is possible to discriminate between states of normal orofacial sensory processing in healthy cats and abnormal sensory processing in cats with oral cancer by using an owner (client)-reported QOL questionnaire (FORQ/CLIENT), clinician pain scoring instrument (UFEPS/VET), and two forms of mQST.

**MATERIALS & METHODS**

**Animals**

A prospective, non-randomized pilot study was conducted. The study protocol and all procedures were approved by the Institutional Animal Care and Use Committee of North Carolina State University (protocol #18-079-O and #18-082-O) and all pet owners provided oral and written informed consent for all procedures. Enrollment was voluntary. While several of the tumor-bearing cats did subsequently enroll in a fully funded therapeutic trial, no financial incentive (or compensation of any type) was provided for enrollment in this study (Lai et al., 2021). Owned pet cats aged >1 year and weighing >2.5 kg were eligible for this study. Fractious cats were excluded during screening. Cats who were noncompliant (i.e., those for whom assessments could not be completed due to temperament or otherwise) were also excluded. Cats were enrolled into two experimental cohorts: (1) tumor-bearing cats; and (2) healthy controls. In the group of cancer-bearing animals, only cats with a pathology-confirmed diagnosis of sublingual SCC were included (either cytology or histopathology). Enrolled cats were required to discontinue systemically administered anti-inflammatory drugs for at least 72 h and opioids for 48 h prior to enrollment.

Complete blood count, serum biochemical analysis, and urinalysis were performed in each cat with oral cancer. For the purposes of clinical cancer staging in cats with SCC, tumor size was measured and if the mandibular lymph nodes were asymmetrical or enlarged, they were aspirated with a fine needle (22 g) for cytologic evaluation. Tumor stage was defined by using an established WHO staging scheme (Owen, 1980). To be enrolled as a healthy control subject, a complete medical history was obtained and physical examination was performed by a veterinarian to ensure the cat was outwardly healthy and free of clinically overt oral disease; neither sedated oral examination nor dental radiography was required. Because cats with sublingual SCC in the present study were >8 years old, and considering that geriatric cats may have subclinical comorbid diseases that can cause pain and/or sensitization (e.g., osteoarthritis) (Lascelles et al., 2007; Gruen et al., 2014), a subset of age-matched healthy control cats were included. In these age-matched controls, lab work (serum biochemistry, hemogram, urinalysis, and thyroid panel) from within the past calendar year was used to supplement physical exam data and ensure “healthy” status. Additionally, while a clear source of potential bias, no attempt was made to mask/blind study personnel to experimental group. Any attempt to do so would have been futile because most cats with oral SCC have clinical signs (e.g., ptyalism, poor body condition score, incomplete grooming) which are readily evident even during distant observation;
while these signs are not specific to a diagnosis of FOSCC, they do readily enable distinction between tumor-bearing cats and healthy controls.

**Outcome measures**

**Owner-Reported Quality of Life questionnaire for cats with oral SCC**

A recently published scale for evaluating QOL in dogs with cancer (CORQ) was used to help design the preliminary FORQ (preFORQ/CLIENT) – Felicne oral cancer Owner-Reported quality of life Questionnaire (see Table S1 and Article S1) (Giuffrida, Farrar & Brown, 2017; Giuffrida et al., 2018). No assumptions were made about validity associated with the CORQ (for dogs) carrying over to FORQ/CLIENT (which was being applied to cats). The preFORQ/CLIENT included a total of 24 questions grouped within four categories: behavior, activity, interaction, and oral/facial discomfort. The initial questions included, and the design, was based on the authors’ experience and discussions, and was considered to have sufficient face validity to move forward (with face validity indicating that the instrument “looks” appropriate for measurement of quality of life, and face validity indicating that the test is designed by experts in the field who believe all relevant face domains are considered) (Brown et al., 2007). Pet owners were requested to score each question with regard to frequency and severity; responses were based on behaviors observed over the preceding 7 days. If a behavior had been seen, the frequency was categorized as: none, rarely (1–2 days), sometimes (3–4 days), usually (5–6 days), or always (every day). Severity was scored as: none, mild, moderate, severe, or very severe. The research team later assigned response numbers, ranging from 0 to 4 with zero reflecting a response of “none” and 4 being either “always” or “very severe”. A total score was calculated; higher scores reflected lower QOL. A 100 mm VAS item was also included at the end of the questionnaire to serve as a single measure of overall QOL; respondents were asked to mark along a line representing somewhere between the “worst imaginable quality of life” (0 mm) and “perfect quality of life” (100 mm). Therefore, on the contrary to FORQ/CLIENT, lower VAS represents lower QOL.

To refine the instrument, each individual item in the preFORQ/CLIENT was analyzed by the non-parametric Mann–Whitney test to evaluate whether that item discriminated between the two groups. Any question with Cohen’s d value that is less than 0.2 or $r < 0.3$ in Spearman’s rank correlation coefficient for both frequency and severity are considered to have small size effect and less relevant to the total preFORQ/CLIENT score (Cohen, 1992; Chan, 2003; Streiner & Norman, 2008); those questions were removed from the questionnaire when creating the “proposed FORQ/CLIENT” (Table 1).

**Clinician pain scoring instrument for assessing orofacial pain in cats with oral SCC**

The UNESP-Botucatu multidimensional composite pain scale for cats with oral diseases was modified to better reflect common ailments and dysfunction that is observed in cats with oral cancer; as mentioned above, the modified scale is referred to here as UFEPS/VET (see Table S2; changes made here are indicated in bold; arterial blood pressure was omitted because of our concerns that its measurement may not be reliable, and can cause undue stress) (Brondani et al., 2013; Stathopoulou et al., 2018). No assumptions were made about
Table 1  The proposed FORQ. The proposed FORQ (feline oral cancer owner-reported quality of life questionnaire) represents a refined version of our pre-FORQ; low-performing items have been removed to improve efficiency of the instrument, and this is the final version being put forward for future and continued validation.

| During the past 7 days, my cat: | No | If YES, how often did your cat have it? | If YES, how severe was it usually? |
|---------------------------------|----|---------------------------------------|-----------------------------------|
|                                 | Rarely | Sometimes | Usually | Always | Mild | Moderate | Severe | Very severe |
| Behavior                        |        |           |         |        |      |          |        |              |
| • Had low energy?               |   ✔    |   ✔       |   ✔     |   ✔    |   ✔   |          |   ✔    |             |
| • Was reluctant to wake up?     |   ✔    |   ✔       |   ✔     |   ✔    |   ✔   |          |   ✔    |             |
| • Had altered mood?             |   ✔    |   ✔       |   ✔     |   ✔    |   ✔   |          |   ✔    |             |
| • Had trouble getting comfortable? |   ✔    |   ✔       |   ✔     |   ✔    |   ✔   |          |   ✔    |             |
| • Growled or groaned when resting? |   ✔    |   ✔       |   ✔     |   ✔    |   ✔   |          |   ✔    |             |
| • Could not maintain hygiene (i.e., grooming)? |   ✔    |   ✔       |   ✔     |   ✔    |   ✔   |          |   ✔    |             |
| • Had decreased appetite?       |   ✔    |   ✔       |   ✔     |   ✔    |   ✔   |          |   ✔    |             |
| • Drank less water than usual?  |   ✔    |   ✔       |   ✔     |   ✔    |   ✔   |          |   ✔    |             |
| Activity                        |        |           |         |        |      |          |        |              |
| • Had trouble with mobility?    |   ✔    |   ✔       |   ✔     |   ✔    |   ✔   |          |   ✔    |             |
| • Did not do what he/she likes (e.g., chasing, playing, etc.)? |   ✔    |   ✔       |   ✔     |   ✔    |   ✔   |          |   ✔    |             |
| • Did not act like his/her normal self? |   ✔    |   ✔       |   ✔     |   ✔    |   ✔   |          |   ✔    |             |
| • Had decreased enjoyment of life? |   ✔    |   ✔       |   ✔     |   ✔    |   ✔   |          |   ✔    |             |
| • Did not sleep well?           |   ✔    |   ✔       |   ✔     |   ✔    |   ✔   |          |   ✔    |             |
| Interaction                     |        |           |         |        |      |          |        |              |
| • Showed a decreased amount of affection? |   ✔    |   ✔       |   ✔     |   ✔    |   ✔   |          |   ✔    |             |
| Oral/facial discomfort          |        |           |         |        |      |          |        |              |
| • Had excessive drooling?       |   ✔    |   ✔       |   ✔     |   ✔    |   ✔   |          |   ✔    |             |
| • Had difficulty eating his/her normal food? |   ✔    |   ✔       |   ✔     |   ✔    |   ✔   |          |   ✔    |             |
| • Was offered and had trouble eating soft food? |   ✔    |   ✔       |   ✔     |   ✔    |   ✔   |          |   ✔    |             |
| • Had trouble lying down his/her head? |   ✔    |   ✔       |   ✔     |   ✔    |   ✔   |          |   ✔    |             |
| • Felt discomfort or pain near the mouth? |   ✔    |   ✔       |   ✔     |   ✔    |   ✔   |          |   ✔    |             |

Notes.

For this final question, please mark an X along the line to show your cat’s overall current quality of life.

Worst Imaginable Quality of Life---------------------------------------------------------------Perfect Quality of Life
validity associated with the UNESP-Botucatu pain scale carrying over to the UFEPS/VET. In the category of miscellaneous behavior, the abnormal behavior of “lick and/or bites the surgical wound” was changed to “licks, has ptyalism and/or chattering (jaw shakes)”. Categories in the instrument pertained to: miscellaneous behavior; reaction to palpation around the mouth and on the head; vocalization; posture; comfort; activity; attitude; or appetite. Each category was scored on a 4-point scale, with 0 indicating normal (or no change) and 3 denoting significantly altered behavior. The clinician gave a score based on the description provided. In the evaluation of appetite, a small amount of canned commercial cat food was offered. In instances where fasting had to be performed at the time of the pain scoring (e.g., in preparation for general anesthesia), the scores were based on the amount of food the cat had consumed at its most recent meal.

**Electronic von Frey**

An EVF apparatus (BIO-EVF3, Bioseb, Chavillecedez, France) was used to assess mechanical sensory thresholds. A plastic pipette tip was loaded on the mounting accessory of a handheld device that can record the applied force. The force was gradually increased manually until a positive response was elicited, with the upper cut-off limit set as 500 g. Positive responses included vocalization, head withdrawal, paw withdrawal, attempt to ‘bat’ or paw at the device, or trying to bite the device. Tests were repeated five times with an interstimulus interval of approximately 1 min. The mean of all five trials was used for data analysis. Lower thresholds indicate greater sensitivity. Measurements were acquired at anatomic sites based on anatomy of the three branches of the trigeminal nerve, which mediates somatosensory input from most of the orofacial region. The mandible and tongue are innervated by the mandibular branches, and the maxillary cutaneous region is innervated by maxillary branches of the trigeminal nerve. Since the input from one area of the face may result in changes in sensitivity in another facial region, we selected four measurement sites (Fig. S1): (1 and 2) just medial to the bilateral mandibulae (intermandibular space), (3) the ipsilateral maxilla, along the path of the maxillary branch, and (4) on the dorsal aspect of the right metacarpus—a site distant to the mouth, which served as the control (Jaaskelainen, 2004). For subjects in the healthy cat cohort, the right maxilla was always tested; other measurement sites (left and right intermandibular space and right metacarpus) were the same as in the test group.

**Cochet-Bonnet aesthesiometer**

The afferent impulses of corneal reflexes are mediated by the ophthalmic division of the trigeminal nerve. Corneal touch threshold (CTT) values were measured using a Luneau Cochet-Bonnet aesthesiometer (Western Ophthalmics, Lynwood, WA) with a monofilament nylon fiber of 0.12 mm diameter, as previously described (Blocker & Van Der Woerdt, 2001). Testing was performed on all enrolled cats, unless they had pre-existing corneal diseases (e.g., corneal scarring, ulcers). The cats were gently manually restrained with their head up; their body was cradled between the restrainer’s chest and forearm. All measurements were made by a single veterinarian, in a quiet and well-lit room. The instrument was held perpendicular to the cornea, and the aesthesiometer filament was applied centrally, on the left cornea. Testing started with a filament length of 60 mm. The
cornea was touched with that length filament, and then if there was no blink response, the filament was shortened by five mm to increase resistance. This process was repeated until a corneal blink was elicited. Once the animal blinked, that same length filament was re-applied a total of 3 times. If that length elicited blink on at least 2 of 3 applications, that length was defined as the CTT. If that length only elicited blink for 1 of 3 applications, progressive shortening continued until a length was identified that did elicit blink in 2 of 3 applications (i.e., 1 of 3 was defined as a false positive, and 2 or 3 of 3 was a true positive). The absence of corneal damage was confirmed via fluorescein staining at the conclusion of each testing session.

For both mQST assays, cats were fully conscious (no sedation) and gently restrained by a single trained technician. No animal was scruffed or forcibly restrained for this testing. Testing was performed in a dedicated room that was quiet, and had no animals in it other than cats; the room is in a veterinary hospital and it is possible that the scent and/or noise of dogs may have been present during some testing sessions, but all reasonable efforts were made to minimize such potential environmental influences.

**Experimental design**

For each outcome measure, we assessed: (1) reliability; (2) discriminatory ability; and (3) responsiveness.

To test reliability (test–retest reliability / intra-rater reliability), Experiment 1 included two measurements on the same subject in both cancer-bearing cats and healthy cats with the assessment being performed by the same person at each timepoint. FORQ/CLIENT did not undergo reliability testing. Measurements of UFEPS/VET, EVF, and COBO aesthesiometer were repeated with at least 6 h between the two tests in the control cats (to facilitate a single outpatient visit) and at least 12 h between the two tests in the cancer cats (overnight, since the cats were to be hospitalized for an unrelated therapeutic intervention trial to begin shortly after the 12 h retest). Tests were performed in the same environment on each subject by the same researcher (YHL) each time. No attempt was made to assess inter-rater reliability within this experiment.

In Experiment 2, cats with oral cancers were compared to healthy cats without oral disease to examine the discriminative validity of each assessment. We performed the FORQ/CLIENT (including VAS), UFEPS/VET, EVF, and COBO aesthesiometer on cats with and without sublingual SCC. Where applicable, initial test (not retest) data from Experiment 1 were used for analysis in Experiment 2. As noted above, a single unmasked observer made all assessments.

Experiment 3 investigated the responsiveness validity of the assessments using cats with sublingual SCC. Assessments were conducted three times (at baseline, 30 min after buprenorphine, and the next day). The buprenorphine (0.3 mg/mL injectable solution, Par Pharmaceutical, Chestnut Ridge, NY) was administered buccally as a liquid, once, with a dose of 0.02 mg/kg as described previously (Robertson et al., 2005).

**Statistics**

Normality of the data was evaluated by the Shapiro–Wilk test. Test–retest reliability (Experiment 1) evaluation was performed using intra-class correlation coefficient (ICC)
and Bland-Altman analysis. In Experiment 2, comparisons of preFORQ/CLIENT and UFEPS/VET between healthy control and cancer cats were performed using the non-parametric Mann–Whitney U-test. Unpaired student t-tests were used to compare the results of EVF and COBO aesthesiometer between two groups. The effect sizes of preFORQ/CLIENT and UFEPS/VET were evaluated by Cohen’s d calculation. Based on the value of Cohen’s d, effect size can be considered low (0.2), medium (0.5), or large (0.8). Item-total correlation was evaluated by Spearman’s rank correlation coefficient. Coefficients with value of $r < 0.3$ were considered poor, $0.3 < r \leq 0.5$ were fair, $0.5 < r \leq 0.8$ were moderately strong, and $>0.8$ were very strong (Chan, 2003). Questions were removed if the Cohen’s $d < 0.2$ or the correlation coefficient $r < 0.3$ (Cohen, 1992; Streiner & Norman, 2008). The reliability of the questions in preFORQ/CLIENT and UFEPS/VET was evaluated by Cronbach’s $\alpha$ analysis (Cronbach, 1951; Taber, 2018). The interpretations of Cronbach’s $\alpha$ were as follows: $<0.35$, low reliability; $0.35$ to $0.7$, medium reliability; $>0.7$, high reliability. Receiver operating characteristic (ROC) curves were built based on total scores for preFORQ/CLIENT (including VAS), EVF, and COBO aesthesiometer to determine the cut-off point. The cut-off point was identified by calculating Youden index (YI), which represents the greatest point of specificity and sensitivity (Streiner & Cairney, 2007). Area under the curve (AUC) $\geq 0.9$ indicates outstanding capacity of discrimination, $0.8$ to $0.9$ is considered excellent, $0.7$ to $0.8$ is acceptable, and $\leq 0.5$ suggests no discrimination (Mandrekar, 2010). In Experiment 3, either the Wilcoxon matched-paired test, or paired t-test, was performed on data collected before buprenorphine and 30 min after buprenorphine. Post-hoc power analyses were performed by using G*Power 3.1.9.7 (Heinrich-Heine-Universität Dusseldorf, Germany). The level of significance was defined as $P < 0.05$. All statistical analyses were performed using commercial software (Prism 7; GraphPad Software, San Diego, CA).

RESULTS

Animals

All healthy control cats were client-owned pet cats specifically recruited for this study. The cats with sublingual SCC (hereafter described as “cancer cats”) were referred to our Radiation Oncology service, from veterinary practices in North Carolina ($n = 6$) and Massachusetts ($n = 1$) between September 2018 and November 2019. Each of these cancer cats was classified as having WHO stage III OSCC (no evidence of lymph node involvement or distant metastasis) at the time of enrollment. A total of 18 healthy cats and seven cancer cats were initially included in the study. However, one cancer cat, and two healthy cats were noncompliant for the EVF assessment; complete orofacial region assessment could not be performed in those two healthy cats, and right forelimb thresholds could not be obtained in the cancer cat. Thus, complete pain/sensitivity evaluations were feasible in 16/18 (89%) healthy cats and 6/7 (86%) cancer cats. The noncompliant animals were excluded from the study, and their data was not included in any analysis (i.e., data analyses reflect data from 16 healthy control cats and 6 cancer cats). Healthy control cats were assessed as a whole, group, and a subset analysis was performed for cats aged $>8$ years (6 out of 18 healthy...
controls; see Age-matched comparison below). Demographics of the cats whose data were included in the analyses are summarized in Table S3.

**Experiment 1: Test –retest reliability**

There were 12 healthy cats and five cancer cats enrolled in Experiment 1 (cancer cat #6 was unable to contribute retest data due to logistical challenges with data collection, not due to subject noncompliance). The test –retest reliability was good for each pain assessment instrument (UFEPS/VET, EVF, and COBO). The UFEPS/VET used in the study can be found as Table S2. The ICC was 0.919 (95% CI [0.776–0.971]). A Bland-Altman plot (Fig. 1A) shows the difference between test and retest on the Y-axis and the mean of two tests on the X-axis; bias between test and retest of UFEPS/VET was 0.5556, which indicated a slightly higher score on the first test. Data from the two tests were positively correlated ($r^2 = 0.77$, $P < 0.0001$; Fig. 1B).

For pressure algometry, the ICC for the maxillary measurement site was 0.73 (95% CI [0.24–0.91]) for average measures. At the metacarpal measurement site, the ICC was 0.68 (95% CI [0.10–0.88]). At the intermandibular sites, these values were 0.73 (95% CI [0.40–0.90]) for the left side, and 0.72 (95% CI [0.37–0.89]) for the right side. The Bland-Altman plot showed most of the differences between the two tests lay between the 95% limits of agreement (LoA) (Fig. S2, left panel). The biases were 5.5, 27.9, 35.3, and 13.6 g in the EVF tests on the right and left intermandibular space, right maxilla, and right metacarpus, respectively. The variability was greater at higher thresholds. The correlations between test and retest were statistically significant at all four testing sites ($P = 0.0006–0.0365$, Fig. S2, right panel), which indicated good test –retest reliability for EVF.

The ICC for COBO measurements was 0.21 (95% CI [−0.29–0.62]) for single measures and 0.34 (95% CI [−0.81–0.76]) for average measures. Bland-Altman plots of COBO measurements showed the bias between two tests was 0 cm and the difference between two tests were within LoA (i.e., between $−1.9$ and $+1.9$) (Fig. S3). The correlation between the
Table 2  Discriminatory analysis of outcome measures.

| Outcome measures                  | Intraclass correlation coefficient | Sensitivity (%) | Specificity (%) | Youden index | Area under curve (AUC ± SEM) | Effect size | Post-hoc power |
|-----------------------------------|------------------------------------|----------------|----------------|--------------|--------------------------------|-------------|---------------|
| FORQ/CLIENT                       | Not available                      | 100            | 100            | 1            | 1 ± 0                          | 6.69        | 1             |
| VAS                               | Not available                      | 100            | 100            | 1            | 1 ± 0                          | 2.14        | 1             |
| UFEPS/VET                         | 0.92                               | 100            | 94             | 0.94         | 0.97 ± 0.04                    | 2.44        | 1             |
| EVF-right intermandibular space   | 0.72                               | 100            | 94             | 0.94         | 0.97 ± 0.04                    | 2.8         | 1             |
| EVF-left intermandibular space    | 0.73                               | 100            | 94             | 0.94         | 0.99 ± 0.02                    | 2.59        | 1             |
| EVF-right maxilla                 | 0.73                               | 100            | 56             | 0.56         | 0.8 ± 0.10                     | 1.26        | 0.81          |
| EVF-right metacarpus              | 0.68                               | 83             | 94             | 0.77         | 0.95 ± 0.05                    | 2.5         | 1             |
| COBO aesthesiometer- left cornea  | 0.21                               | 100            | 75             | 0.75         | 0.92 ± 0.06                    | 2.08        | 1             |

two tests was not statistically significant ($P = 0.1823$), but the CT Ts in cats with sublingual cancers were generally higher than control cats.

Since our test–retest experiments have shown good reliability, we used the first measurement for statistical analysis in Experiment 2: discriminatory validity (except for FORQ/CLIENT, which was answered once by the cat owners in the study).

**Experiment 2: Discriminatory validity**

*Preliminary feline oral cancer owner-reported quality of life questionnaire (preFORQ/CLIENT)*

There were 16 healthy cats and six cancer cats from whom data were included in Experiment 2. The discriminatory analysis is summarized in Table 2. The mean ± SD of preFORQ/CLIENT total score in cancer cats was significantly higher (49.67 ± 7.6) than healthy cats (3 ± 6.3, $P < 0.0001$, Fig. 2A). The VAS was significantly lower in cats with sublingual SCC than healthy controls ($P < 0.0001$, Fig. 2B); remember: the lower VAS suggests lower QOL, which is opposite of how the FORQ/CLIENT scores change relative to QOL. The mean ± SD of VAS in cancer cats was 55.5 ± 23.65 mm, compared to 93.3 ± 7.9 mm in healthy cats. At the cut-off value of $<74.5$ mm, the sensitivity and specificity of VAS were both 100%, with the YI of 1. As would be expected, the total scores for preFORQ/CLIENT and VAS from all respondents were inversely proportional ($r = -0.77$, $r^2 = 0.6$, $P < 0.0001$, Fig. 2C). The mean ± SD of subtotal scores in terms of frequency and severity were both significantly higher in cancer patients (25.83 ± 6.37 and 21.5 ± 4.04, $P < 0.0001$, respectively, Figs. 2D and 2E) than healthy cats (mean = 1.68 ± 3.52 and 1.25 ± 2.7, respectively). Apart from the category of “interaction”, the total scores in all other categories (i.e., general behavior, activity, and orofacial discomfort) were significantly higher in cancer cats than in healthy controls ($P < 0.0001$, respectively, Table S4). The Cronbach’s $\alpha$ value of preFORQ/CLIENT was 0.91, which suggests strong reliability (Cronbach, 1951).

Each question item was assigned a number for further analysis (Table S1). By reviewing the heat plot, the most frequent observations in cancer cats were excessive drooling and trouble eating (QF-19 and -20, Fig. S4A); in regards to severity, the mean score in drooling were the highest in cancer cats when compared to other questions (QS-19, Fig. S4B).
Worse QOL in cats with oral cancer pain is evidenced by both: (A) significantly higher total scores; and (B) significantly lower VAS in cancer cats. (C) The correlation between preFORQ/CLIENT total scores and VAS was statistically significant ($P < 0.0001$, $r = -0.77$, $r^2 = 0.6$). (D) The frequency and (E) severity scores were significantly higher in cats with oral cancer pain, $**P < 0.0001$, Mann–Whitney test. Each dot represents the score of individual cats. Values from healthy cats are denoted by open dots; triangular shaped dots denote aged healthy control; closed/solid dots represent cats with sublingual SCC. All error bars depict SEM.

Analysis of individual questions showed that 11 of 24 questions were able to discriminate between cancer and healthy cats (Table S5). Using a cut-off point of $<27.5$ for the sum of frequency and severity scores, both the sensitivity and specificity of preFORQ/CLIENT were 100% and the YI was 1.

To refine our questionnaire, and define a FORQ/CLIENT that can be used in future research, we excluded those questions with Cohen’s $d$ value $< 0.2$ or $r < 0.3$ in Spearman rank correlation coefficient for both frequency and severity. The refined, proposed FORQ/CLIENT is a 19-item questionnaire (Table 1). The removed questions were: had trouble positioning to defecate/urinate (Q-09), lost balance (Q-11), unwilling to be accompanied (Q-16), did not like to be pet (Q-18), and defensive behavior when touching the head (Q-24). The refined FORQ/CLIENT has an improved Cronbach $\alpha$ value (0.92) and the sensitivity and specificity remained 100% when using a cut-off point of $<25.5$.

**Feline orofacial pain scale for cancers (UFEPS/VET)**

Compared to healthy cats, cancer cats had significantly higher total scores in UFEPS/VET, indicating that cats with sublingual SCC exhibit more pain-related behaviors (Fig. 3A). Cancer cats had significantly higher scores in miscellaneous behavior ($P < 0.0001$), mouth palpation ($P = 0.0043$), comfort ($P = 0.0021$), activity ($P = 0.0349$), attitude ($P = 0.0075$), and appetite ($P = 0.0002$), as shown in (Fig. 3B). However, head palpation, vocalization, and posture did not show significant differences between healthy cats and cats with
sublingual SCC. Cronbach’s $\alpha$ was 0.84, indicating high reliability. With a cut-off point of $>3.5$ for total score, the YI was 0.94; at this cut-off, sensitivity and the specificity were 100 and 94%, respectively. The AUC was $0.97 \pm 0.04$, indicating that UFEPS/VET has high discriminatory capacity. The total UFEPS/VET score was positively correlated with the preFORQ/CLIENT score ($r^2 = 0.58$, $P = 0.0002$, Fig. 3C) and the proposed, refined FORQ/CLIENT score ($r^2 = 0.72$, $P < 0.0001$).

In the miscellaneous behavioral category, the majority of observations in cancer cats were: 'laying down and quiet' ($n = 5/6$), and 'licks, ptyalism, or chattering' ($n = 4/6$) (see Table S2). In attitude evaluation, five out of six cats with sublingual SCC were uninterested in interacting with the observer and one cat showed both disinterest in the observer and indifference to its surroundings. Cats with sublingual SCC tended to show interest in food, but did not continue consumption after a few bites.
Cohen’s d values for all items in UFEPS/VET were large (>0.8), except for “vocalization” (d = −0.04). Spearman rank correlation coefficient test showed “head palpation” had low correlation to the total score (r = 0.25). After removing “vocalization” and “head palpation”, the Cronbach’s α = 0.88; at a cut-off point of >3.5, the sensitivity, specificity, and YI remained 100%, 94%, and 0.94, respectively, but the AUC increased to 0.98 ± 0.03.

**Electronic von Frey and Cochet-Bonnet Aesthesiometer**

Cats with sublingual SCC were significantly more sensitive to pressure (*i.e.*, had lower mQST thresholds) at both sides of the intermandibular space (Figs. 4A and 4B, *P* < 0.0001 on both right and left side), and at the right maxillary region (Fig. 4C, *P* = 0.0273). The mean differences of the mechanical sensory threshold between healthy and cancer cats on the right intermandibular space, left intermandibular space, and right maxillary region were 158.5 ± 31.02, 152.2 ± 31.45, and 101.1 ± 45.28 grams, respectively. Based on the ROC curve, the sensitivity can reach 100% at either side of intermandibular space, and the specificity is 94%. At right maxillary region, the sensitivity and specificity were 100 and 56%, respectively. Interestingly, decreased thresholds were observed at the metacarpal site (*P* = 0.0002) in cancer cats compared to healthy controls (227 ± 32.32 versus 378.7 ± 16.43 g, Fig. 4D). The sensitivity and specificity of EVF on metacarpal region were 83.33 and 93.75%, respectively. The AUC ranged from 0.8 to 0.95 at all EVF test sites, which indicates excellent discriminatory ability. In cancer cats, five out of six cats had tumors that originated from the right side and one out of the six cats (FOSCC#4) had a tumor originating from the left side. However, all of the cats had masses that crossed the midline and occupied the base of the tongue. There was no significant difference between the mQST thresholds at ipsilateral and contralateral sides of the intermandibular region in cats with sublingual SCC (Fig. 4E, *P* = 0.883).

Previous work has demonstrated that healthy domestic short-haired cats have similar CTT values in the right and left eyes (*Blocker & Van DerWoerdt, 2001*). To reduce procedure time and stress on animals, we only performed the COBO aesthesiometer test on left corneas. In contrast to the threshold value measured by EVF, higher CTT values indicate that a subject is more sensitive to corneal touch. CTT values from the left cornea showed that cats with sublingual SCC were more sensitive than control animals (Fig. 4F, *P* = 0.0009); on average, healthy cats were able to sustain higher pressures (1.17 ± 0.3 cm shorter filament). At the cut-off point of >2.25 cm, sensitivity and specificity of COBO for discrimination between cancer cats and healthy cats were 100 and 75%, respectively. Based on the ROC curve, the COBO has outstanding discriminatory capacity (AUC 0.92 ± 0.06).

Sex differences have been shown when measuring orofacial sensitivity using QST in humans (*Costa et al., 2019*). We compared the threshold values measured by EVF and COBO aesthesiometer between healthy castrated males (*n* = 6) and spayed females (*n* = 10), but did not identify statistically significant differences between sexes (Fig. S5). There were too few cancer-bearing cats to make a statistically relevant comparison.

**Age-matched comparison**

In a subset analysis, the outcome measurements from 6 geriatric cats (aged 8-15 years, with median of 10 years) in the healthy control group were compared to the 6 cancer
Figure 4  Mechanical quantitative sensory tests (QST). Cats with sublingual SCC were more sensitive to pressure (EVF test) at the (A) right and (B) left intermandibular test sites, (C) maxillary region, and (D) right metacarpus. (E) There was no significant difference between the QST values on the ipsilateral (tumor) side versus the opposite (contralateral) side of the mandibular region in cats with sublingual SCC; paired t-test. (F) Cats with oral cancer were more sensitive to mechanical stimuli on central corneal touch (CCT) measured with the COBO aesthesiometer. Each dot represents the measurement of individual cats. Values from healthy cats are denoted by open dots; triangular shaped dots denote aged healthy control; closed/solid dots represent cats with sublingual SCC. ∗P < 0.05, ∗∗∗P < 0.001, ∗∗∗P < 0.0001, unpaired t-test. All error bars depict SEM.

cats. The body weight (mean ± SD) of cancer cats was less (3.7 ± 0.58 kg) than healthy counterparts (4.7 ± 0.56 kg, P = 0.0106). Cancer cats had significantly higher scores in terms of preFORQ/CLIENT and UFEPS/VET than aged healthy cats (Fig. S6). Cancer cats also showed significantly decreased sensory thresholds in EVF and COBO aesthesiometer tests (Fig. S6 and Table S6).

Experiment 3: Responsiveness validity
UFEPS/VET, EVF, and COBO measurements were performed before and 30 min after administering an analgesic drug (buprenorphine 0.02 mg/kg, buccally) to six cats with SCC of the tongue. The mechanical sensory threshold at the ipsilateral intermandibular site, and CTT values were significantly improved after buprenorphine administration (Fig. 5, the details can be found in Table S7). The mechanical sensory threshold increased by 66.85 ± 24.48 g (P = 0.04) at the ipsilateral intermandibular site after giving buprenorphine, and after buprenorphine, cancer cats could withstand corneal pressures that were higher (1.17 ± 0.33 cm shorter filament; P = 0.017). Although not statistically significant, other tests (including UFEPS/VET, and EVF at other sites) also showed a trend toward decreased pain/sensitization after providing buprenorphine; this is notable given the small sample size, where lack of statistical significance may reflect true biology or statistical error. Based
Figure 5  Analgesic responsiveness of each outcome measure in cats with oral cancer. Responsiveness testing of outcome measures in cats with oral cancers via: (A) UFEPS/VET; EVF testing at the (B) ipsilateral and (C) contralateral intermandibular sites, (D) ipsilateral maxilla, and (E) right metacarpus; and (F) COBO aesthesiometer testing. Cats had altered thresholds in orofacial pain measurements after buccal administration of buprenorphine; thresholds returned to baseline by the next morning. Significantly increased mechanical sensory thresholds at the ipsilateral intermandibular sites were observed 30 min after buprenorphine administration, and similarly, the length of COBO filament required to elicit response became shorter (i.e., the pressure threshold increased) with buprenorphine administration (P = 0.04 and 0.02, respectively, see Table S7).

on post hoc power analysis, with the exception of COBO testing, power was low (< 0.8) for all comparisons in Experiment 3 (Table S7). Nonetheless, results are biologically plausible, and for each assay, the pain score/sensitivity returned to baseline (i.e., pre-buprenorphine levels) by the next morning.

DISCUSSION

This study reports on the adaptation and initial testing of various outcome measures that should enable robust research in a naturally occurring feline model of oral cancer pain. Based on our preliminary studies, the methods described herein appear to have good intra-rater reliability within a single observer; furthermore, we provide evidence that these assays effectively discriminate between healthy and tumor-bearing cats, and some are responsive to analgesic therapy. Interestingly, our results also suggest that cats with tongue cancer not only develop pain in their mouth, but also seem to have regional peripheral, and widespread sensitization; this is consistent with the widespread somatosensory sensitization that is reported in human HNC patients and which can be measured in other animal models of oral cancer pain (Ye et al., 2017).

One goal of this study was to develop methods for assessing pain in a naturally occurring feline model of oral cancer. Pain can affect overall QOL, thus in our study, we attempted to measure QOL rather than health-related QOL, which only focuses on the impact of a
specific illness on QOL (Reid, Nolan & Scott, 2018). Given that a canine owner-reported QOL questionnaire for cancer patients had been developed and published, we used this to guide the initial construction of an instrument to evaluate the QOL of cats with oral cancers. Through basing this instrument on the canine cancer QOL instrument, and discussions between the authors, we believed the initial FORQ/CLIENT had sufficient face validity to move forward into testing and refinement. Our initial (preliminary) version of the FORQ/CLIENT showed high reliability and good discriminative function; it distinguished healthy cats from those with sublingual SCC. However, some individual questions’ effect size was small, leading us to omit them from the proposed version of the FORQ/CLIENT.

In our study, cats with oral cancers did not have significant mood alteration, reluctance to wake up, or vocalization when resting, and they did have normal interactions with the owners, which is different from observations made in canine cancer patients (Giuffrida et al., 2018). This discrepancy may be due to the natural characteristics of different species. We also found that “less drinking” was not a good indicator in cats with sublingual cancers. Although cats with sublingual cancers decreased their normal food intake, it is known that mouth dryness and pain are common in human patients with advanced cancers. We therefore theorize that increased water intake could possibly indirectly indicate mouth dryness and/or pain in these tongue cancer-bearing cats (Oneschuk, Hanson & Bruera, 2000). Overall, similarly negatively altered QOL has been reported in human HNC patients (Gotay & Moore, 1992; Terrell et al., 2004), which supports the potential translational utility of this outcome measure.

To complement these pet owner derived assessments of QOL, we also tested a clinician-based clinical metrology instrument focused on measuring the impact of oral pain. UFEPS/VET scores were significantly greater for oral cancer-bearing cats than control cats, and UFEPS/VET scores were highly correlated to FORQ/CLIENT responses. The UFEPS/VET assesses various behavioral changes that indicate pain and/or discomfort, not only around the oral region, but also in terms of general comfort, activity and attitude. The Cohen’s d value shows small effect size for vocalization, and the Spearman rank correlation coefficient showed head palpation related poorly to the total score; thus future iterations of the UFEPS/VET might exclude these parameters. Most cancer-bearing cats maintained interest in food; however, tumor-associated dysphagia is known to reduce food intake (which is reflected in the “difficulty eating food” data in FORQ/CLIENT); thus, in future iterations of the UFEPS/VET, we may consider revising the appetite scoring to reflect this disconnect between appetite and ability to successfully prehend food. Additionally, the value of UFEPS/VET may be improved through the incorporation of facial expression assessment; both ear position and muzzle shape have been used to in feline acute pain evaluations (Holden et al., 2014; Reid et al., 2017; Evangelista et al., 2019). Although a clinician-based pain assessment has not been developed specifically for cancer pain in humans, behavioral observation scales produce similar results in nonverbal elderly adults with cancers and chronic pain (Passik et al., 2004; Bjoro & Herr, 2008); this supports the potential translational utility of the UFEPS/VET in cats with oral cancer. Both FORQ/CLIENT and the UFEPS/VET should undergo additional testing including repeating our work, readability testing and additional validity testing, including inter-rater
reliability, responsiveness testing with other analgesics, further face validity testing and
criterion validity testing.

We used an EVF and a COBO aesthesiometer to evaluate mechanical sensitivity. The
EVF thresholds measured on the maxilla of healthy cats were variable; this could be due to
the presence of highly sensitive tactile hairs of the vibrissal pad (Gogan et al., 1981; Grant
et al., 2013). Even with that variability, we demonstrate here that cats with sublingual cancer
were more sensitive to mechanical pressure near the mouth, and, interestingly at a distant
anatomic site. Increased sensitivity around the mandibular region, maxilla, and eyes may be
partly related to peripheral sensitization driven by locally produced nociceptor sensitizers,
but part may also be driven by more central changes affecting multiple branches of the
trigeminal nerve (Woolf, 2011; Vardeh & Naranjo, 2017). The three trigeminal branches
(i.e., ophthalmic, maxillary, and mandibular nerve) anatomically converge at the trigeminal
ganglia, and signaling cross-talk is also possible at the brainstem (Walker, 1990). This
pathway of signal transduction explains the maxillary and corneal hypersensitivity we
observed. Peripheral sensitization may be due to inflammation, tumor cells infiltrating into
the nerve fibers or other tumor-related factors (trauma, acidification, etc.) that increases
the responsiveness and activity of nociceptors (Vardeh & Naranjo, 2017). The finding that
cats with sublingual SCC had relatively low nociceptive thresholds at their metacarpus (in
the absence of a tumor or other injury on their paw) may indicate central sensitization,
or a generalized peripheral sensitization (Woolf, 2011; Vardeh & Naranjo, 2017). This is
consistent with the finding that mice with experimentally-induced tongue SCC display
widespread somatosensory sensitization (Ye et al., 2017).

The QST measures that were studied herein were able to distinguish healthy cats and cats
with sublingual cancer. However, it must be remembered that QST results are likely affected
by the “pain history”, underlying chronic pain, and stress. To address such potential bias,
we performed a subset analysis in age-matched cats that came to the veterinary hospital
for regular check-ups and/or vaccination, rather than simply visiting to participate in this
study. This analysis supports our conclusion that the observed hypersensitivities were
related to oral cancer. To that end, it is important to reflect upon the low ICC values
reported herein for both mQST assays. Here, the lack of stability over time is not surprising
given the small sample size, and this result is also similar to what has been reported for other
forms of QST utilized in companion animals (Knazovicky et al., 2017). Thus, given our
existing knowledge, it is important to consider that a well-designed experiment utilizing
these assays must include carefully chosen concurrent controls.

To understand how well these QST data recapitulate the human oral cancer pain
condition would require comparing our results with QST data from affected people.
However, QST has been primarily used in human cancer patients to characterize the
somatosensory changes that come with chemotherapy-induced peripheral neuropathy;
data on OSCC related pain are lacking (Martland et al., 2020). Similar to the human
condition is that pain is often restricted to the local tumor site. Dissimilar is that we
measured spontaneous pain, whereas human oral SCC patient seem to report pain most
frequently as having been evoked by such activities as eating and speaking.
As an initial evaluation of whether the methods used in the present study are able to detect reduced cancer pain after analgesic treatment, we performed assessments before and after administration of buprenorphine. Buprenorphine is an opioid that has been primarily used in cats for acute surgical pain (Steagall et al., 2009). Oral transmucosal administration has been shown to relieve pain and the maximum plasma concentration occurs about 30 min after application (Robertson et al., 2005; Stathopoulou et al., 2018). While buprenorphine may cause sedation, which could potentially confound our results, we saw significantly reduced sensitivities at both of the ipsilateral intermandibular test sites, and on the corneal surface after buprenorphine administration. This suggests that the instruments described herein are responsive to, and appear able to measure the effectiveness of analgesic interventions. Future validation studies should seek to understand whether the assays are also responsive to other analgesics. For example, it would be logical to test a non-steroidal anti-inflammatory drug; that was not done here due to concern for renal injury, which was heightened by the fact that after these pain measurements were made, each cat underwent general anesthesia for cancer treatment.

There are several limitations to the pilot work presented herein. First, while control cats did undergo thorough physical examination by a trained veterinarian, sedated oral examination and dental radiography were not performed, thus it is uncertain whether these cats were free of any dental disease. Second, while physical restraint for mQST was gentle and minimal, that handling and the environment (a hospital setting) could have affected nocifensive (behavioral) responses. Third, in Experiment 1, the amount of time between measurements (no less than 6-12 h) may have been too short; that interval was chosen because it was viewed as a balance between allowing time between tests while also minimizing the amount of hospitalization required for each cat. That latter point is an important consideration since clinic/hospital visits are potentially stressful to the animal, and that stress could influence test results. Nonetheless, is possible that during the second assessment, the observer may have been influenced by memory of answers to the first assessment. Strategies to reduce such potential bias must be considered for future validation work. Finally, in Experiment 2, our ability to rigorously assess discriminatory validity is compromised by failure to effectively mask the observer to experimental group; therefore, construct validity and responsiveness are subject to bias. Unfortunately, the frequency with which oral cancer afflicted cats display overt clinical signs of disease that are evident even to non-expert observers is high, and thus effective masking of well-trained researchers is viewed by these authors as being an unavoidable limitation of the work. Next steps in validation of these assays will be to larger scale studies, with incorporation of multiple observers such that we can rigorously assess inter-rater reliability.

CONCLUSIONS

Together, the methods described in this manuscript can be used to provide what we believe is a comprehensive assessment of orofacial pain phenotypes in cats with oral cancer. If these instruments are to be successfully used for rigorous assessment of cancer-related pain and/or analgesic efficacy, additional large-scale inter-institutional studies should be performed to
ensure that reproducible results are achievable. It would also be ideal to understand assay responses in the setting of various cancer treatments (e.g., radiotherapy, chemotherapy, and surgery). Another important finding was that cats appear to have pain at the local/primary tumor site, and also have evidence of widespread somatosensory sensitization. Future work should aim to: (1) reaffirm this finding, (2) more comprehensively characterize the widespread changes and their mechanistic underpinnings, and (3) determine whether similar changes occur in humans, particularly in the absence of distant metastatic disease.

**ACKNOWLEDGEMENTS**

The authors thank Ms. Karen Marcus and the NC State Clinical Studies Core for technical assistance, and Drs. David Dorman and Santosh Mishra for thoughtful advice on interpretation of results.

**ADDITIONAL INFORMATION AND DECLARATIONS**

**Funding**

This work was funded through: a research grant from the Winn Feline Foundation, contributions from the Paul and Lea Levine Foundation, and support from the NC State University Comparative Medicine Institute, and College of Veterinary Medicine. There was no additional external funding for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Grant Disclosures**

The following grant information was disclosed by the authors:
Winn Feline Foundation.
NC State University Comparative Medicine Institute, and College of Veterinary Medicine.

**Competing Interests**

The authors declare there are no competing interests.

**Author Contributions**

- Yen-Hao Erik Lai conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
- B. Duncan X. Lascelles conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.
- Michael W. Nolan conceived and designed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.

**Animal Ethics**

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

The Institutional Animal Care and Use Committee of North Carolina State University provided full approval for this research (protocol #18-079-O and #18-082-O).
Data Availability
The following information was supplied regarding data availability:

Data for the FORQ, the revised FORQ, and data from healthy cats are available in the Supplemental Files.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.11984#supplemental-information.

REFERENCES

Barrett P, Scagliotti R, Merideth R. 1991. Absolute corneal sensitivity and corneal trigeminal nerve anatomy in normal dogs. Progress in Veterinary & Comparative Ophthalmology 1:245–254.

Belli M, De Oliveira AR, de Lima MT, Trindade PHE, Steagall PV, Luna SPL. 2021. Clinical validation of the short and long UNESP-Botucatu scales for feline pain assessment. PeerJ 9:e11225 DOI 10.7717/peerj.11225.

Benito J, De Puy V, Hardie E, Zamprogno H, Thomson A, Simpson W, Roe S, Hansen B, Lascelles BDX. 2013a. Reliability and discriminatory testing of a client-based metrology instrument, feline musculoskeletal pain index (FMPI) for the evaluation of degenerative joint disease-associated pain in cats. Veterinary Journal 196:368–373 DOI 10.1016/j.tvjl.2012.12.015.

Benito J, Hansen B, Depuy V, Davidson GS, Thomson A, Simpson W, Roe S, Hardie E, Lascelles BDX. 2013b. Feline musculoskeletal pain index: responsiveness and testing of criterion validity. Journal of Veterinary Internal Medicine 27:474–482 DOI 10.1111/jvim.12077.

Bilgic O, Duda L, Sánchez MD, Lewis JR. 2015. Feline oral Squamous cell carcinoma: clinical manifestations and literature review. Journal of Veterinary Dentistry 32:30–40 DOI 10.1177/089875641503200104.

Bjoro K, Herr K. 2008. Assessment of pain in the nonverbal or cognitively impaired older adult. Clinics in Geriatric Medicine 24:237–262 DOI 10.1016/j.cger.2007.12.001.

Blocker T, Van Der Woerdt A. 2001. A comparison of corneal sensitivity between brachycephalic and domestic short-haired cats. Veterinary Ophthalmology 4:127–130 DOI 10.1046/j.1463-5224.2001.00189.x.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 68:394–424 DOI 10.3322/caac.21492.

Briley JD, Williams MD, Freire M, Griffith EH, Lascelles BDX. 2014. Feasibility and repeatability of cold and mechanical quantitative sensory testing in normal dogs. Veterinary Journal 199:245–250 DOI 10.1016/j.tvjl.2013.10.025.

Brondani JT, Luna SPL, Padovani CR. 2011. Refinement and initial validation of a multidimensional composite scale for use in assessing acute postoperative pain in cats. American Journal of Veterinary Research 72:174–183 DOI 10.2460/ajvr.72.2.174.
Brondani JT, Mama KR, Luna SPL, Wright BD, Niyom S, Ambrosio J, Vogel PR, Padovani CR. 2013. Validation of the English version of the UNESP-Botucatu multidimensional composite pain scale for assessing postoperative pain in cats. *BMC Veterinary Research* 9:143 DOI 10.1186/1746-6148-9-143.

Brown DC, Boston RC, Coyne JC, Farrar JT. 2007. *American Journal of Veterinary Research* 68(6):631–637 DOI 10.2460/ajvr.68.6.631.

Calvo G, Holden E, Reid J, Scott EM, Firth A, Bell A, Robertson S, Nolan AM. 2014. Development of a behaviour-based measurement tool with defined intervention level for assessing acute pain in cats. *Journal of Small Animal Practice* 55:622–629 DOI 10.1111/jsap.12280.

Chan YH. 2003. Biostatistics 104: correlation analysis. *Singapore Medical Journal* 44:614–619.

Chan-Ling T. 1989. Sensitivity and neural organization of the cat cornea. *Investigative Ophthalmology and Visual Science* 30:1075–1082.

Cohen J. 1992. A power primer. *Psychological Bulletin* 112:155–159 DOI 10.1037/0033-2909.112.1.155.

Costa YM, De Araújo Júnior ENS, Fiedler LS, De Souza PRJ, Silva LLCP, Ferreira DMAO, Conti PCR, Bonjardim LR. 2019. Reproducibility of quantitative sensory testing applied to musculoskeletal orofacial region: site and sex differences. *European Journal of Pain (United Kingdom)* 23:81–90 DOI 10.1002/ejp.1287.

Cronbach LJ. 1951. Coefficient alpha and the internal structure of tests. *Psychometrika* 16:297–334 DOI 10.1007/BF02310555.

Evangelista MC, Watanabe R, Leung VSY, Monteiro BP, O'Toole E, Pang DSJ, Steagall PV. 2019. Facial expressions of pain in cats: the development and validation of a Feline Grimace Scale. *Scientific Reports* 9(1):19128 DOI 10.1038/s41598-019-55693-8.

Giuffrida MA, Brown DC, Ellenberg SS, Farrar JT. 2018. Development and psychometric testing of the canine owner-reported quality of life questionnaire, an instrument designed to measure quality of life in dogs with cancer. *Journal of the American Veterinary Medical Association* 252:1073–1083 DOI 10.2460/javma.252.9.1073.

Giuffrida MA, Farrar JT, Brown DC. 2017. Psychometric properties of the canine symptom assessment scale, a multidimensional owner-reported questionnaire instrument for assessment of physical symptoms in dogs with solid tumors. *Journal of the American Veterinary Medical Association* 251:1405–1414 DOI 10.2460/javma.251.12.1405.

Gogan P, Guéritaud JP, Horscholle-Bossavit G, Tyc-Dumont S. 1981. The vibrissal pad as a source of sensory information for the oculomotor system of the cat. *Experimental Brain Research* 44:409–418 DOI 10.1007/BF00238833.

Gotay CC, Moore TD. 1992. Assessing quality of life in head and neck cancer. *Quality of Life Research* 1:5–17 DOI 10.1007/BF00435431.

Grant RA, Haidarliu S, Kennerley NJ, Prescott TJ. 2013. The evolution of active vibrissal sensing in mammals: Evidence from vibrissal musculature and function in the marsupial possum Monodelphis domestica. *Journal of Experimental Biology* 216:3483–3494 DOI 10.1242/jeb.087452.
Gruen ME, Griffith E, Thomson A, Simpson W, Lascelles BDX. 2014. Detection of clinically relevant pain relief in cats with degenerative joint disease associated pain. *Journal of Veterinary Internal Medicine* 28:346–350 DOI 10.1111/jvim.12312.

Gruen ME, Griffith EH, Thomson AE, Simpson W, Lascelles BDX. 2015. Criterion validation testing of clinical metrology instruments for measuring degenerative joint disease associated mobility impairment in cats. *PLOS ONE* 10(7):e0131839 DOI 10.1371/journal.pone.0131839.

Hadjistavropoulos T, Craig KD, Martin N, Hadjistavropoulos H, McMurtry B. 1997. Toward a research outcome measure of pain in frail elderly in chronic care. *Pain Clinic* 10:71–79.

Holden E, Calvo G, Collins M, Bell A, Reid J, Scott EM, Nolan AM. 2014. Evaluation of facial expression in acute pain in cats. *Journal of Small Animal Practice* 55:615–621 DOI 10.1111/jsap.12283.

Infante-Cossio P, Torres-Carranza E, Cayuela A, Gutierrez-Perez JL, Gili-Miner M. 2009. Quality of life in patients with oral and oropharyngeal cancer. *International Journal of Oral and Maxillofacial Surgery* 38:250–255 DOI 10.1016/j.ijom.2008.12.001.

Jääskeläinen SK. 2004. Clinical neurophysiology and quantitative sensory testing in the investigation of orofacial pain and sensory function. *Journal of Orofacial Pain* 18:85–107.

Klinck MP, Gruen ME, del Castillo JRE, Guillot M, Thomson AE, Heit M, Lascelles BDX, Troncy E. 2018a. Development and preliminary validity and reliability of the montreal instrument for cat arthritis testing, for use by caretaker/owner, MI-CAT(C), via a randomised clinical trial. *Applied Animal Behaviour Science* 200:96–105 DOI 10.1016/j.applanim.2017.11.013.

Klinck MP, Mogil JS, Moreau M, Lascelles BDX, Flecknell PA, Poitte T, Troncy E. 2017. Translational pain assessment: could natural animal models be the missing link? *Pain* 158:1633–1646 DOI 10.1097/j.pain.0000000000000978.

Klinck MP, Monteiro BP, Lussier B, Guillot M, Moreau M, Otis C, Steagall PVM, Frank D, Martel-Pelletier J, Pelletier JP, del Castillo JRE, Troncy E. 2018b. Refinement of the Montreal Instrument for Cat Arthritis Testing, for Use by Veterinarians: detection of naturally occurring osteoarthritis in laboratory cats. *Journal of Feline Medicine and Surgery* 20:728–740 DOI 10.1177/1098612X17730172.

Knazovicky D, Helgeson ES, Case B, Thomson A, Gruen ME, Maixner W, Lascelles BDX. 2017. Replicate effects and test–retest reliability of quantitative sensory threshold testing in dogs with and without chronic pain. *Veterinary Anaesthesia and Analgesia* 44:615–624 DOI 10.1016/j.vaa.2016.08.008.

Kunz M, Scharmann S, Hemmeter U, Schepelmann K, Lautenbacher S. 2007. The facial expression of pain in patients with dementia. *Pain* 133:221–228 DOI 10.1016/j.pain.2007.09.007.

Lai YHE, Morhard R, Ramanujam N, Nolan MW. 2021. Minimally invasive ethyl cellulose ethanol ablation in domesticated cats with naturally occurring head and neck cancers: six cats. *Veterinary and Comparative Oncology* Epub ahead of print Feb 14 2021 DOI 10.1111/vco.12687.
Lascelles BDX, Brown DC, Conzemius MG, Gill M, Oshinsky ML, Sharkey M. 2019. Measurement of chronic pain in companion animals: discussions from the pain in animals workshop (PAW) 2017. *Veterinary Journal* 250:71–78 DOI 10.1016/j.tvjl.2019.07.001.

Lascelles BDX, Hansen BD, Roe S, De Puy V, Thomson A, Pierce CC, Smith ES, Rowinski E. 2007. Evaluation of client-specific outcome measures and activity monitoring to measure pain relief in cats with osteoarthritis. *Journal of Veterinary Internal Medicine* 21(1):410–416 DOI 10.1892/0891-6640(2007)21[410:EOCOMA]2.0.CO;2.

Lascelles DX, Flecknell PAS. 2010. Do animal models tell us about human pain? IASP Pain Clinical Updates XVIII:1–6.

Lynch S, Savary-Bataille K, Leeuw B, Argyle DJ. 2011. Development of a questionnaire assessing health-related quality-of-life in dogs and cats with cancer. *Veterinary and Comparative Oncology* 9:172–182 DOI 10.1111/j.1476-5829.2010.00244.x.

Macfarlane TV, Wirth T, Ranasinghe S, Ah-See KW, Renny N, Hurman D. 2012. Head and neck cancer pain: systematic review of prevalence and associated factors. *Journal of Oral and Maxillofacial Research* 3(1):e1 DOI 10.5037/jomr.2012.3101.

Machin H, Kato E, Adami C. 2019. Quantitative sensory testing with Electronic von Frey Anesthesiometer and von Frey filaments in nonpainful cats: a pilot study. *Veterinary Anaesthesia and Analgesia* 46:251–254 DOI 10.1016/j.vaa.2018.09.003.

Mandrekar JN. 2010. Receiver operating characteristic curve in diagnostic test assessment. *Journal of Thoracic Oncology* 5:1315–1316 DOI 10.1097/JTO.0b013e3181ec173d.

Martland ME, Rashidi AS, Bennett MI, Fallon M, Jones C, Rolke R, Mulvey MR. 2020. The use of quantitative sensory testing in cancer pain assessment: a systematic review. *European Journal of Pain* 24:669–684 DOI 10.1002/epj.1520.

Matos R, Wang K, Jensen JD, Jensen T, Neuman B, Svensson P, Arendt-Nielsen L. 2011. Quantitative sensory testing in the trigeminal region: Site and gender differences. *Journal of Oral and Facial Pain and Headache* 25:161–169.

McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, Lau J, Carr D. 2003. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. *Journal of Pain* 41:231–256 DOI 10.1016/S1526-5900(03)00556-X.

Mogil JS. 2009. Animal models of pain: progress and challenges. *Nature Reviews Neuroscience* 10:283–294 DOI 10.1038/nrn2606.

Monteiro BP, De Lorimier LP, Moreau M, Beauchamp G, Blair J, Lussier B, Pelletier JP, Troncy E. 2018. Pain characterization and response to palliative care in dogs with naturally-occurring appendicular osteosarcoma: an open label clinical trial. *PLOS ONE* 13: DOI 10.1371/journal.pone.0207200.

Niv D, Kreitler S. 2001. Pain and quality of life. *Pain Practice* 1:150–161 DOI 10.1046/j.1533-2500.2001.01016.x.

Oneschuk D, Hanson J, Bruera E. 2000. A survey of mouth pain and dryness in patients with advanced cancer. *Supportive Care in Cancer* 8:372–376 DOI 10.1007/s005200050005.
Owen L. 1980. TNM Classification of tumours in domestic animals. World Health Organisation 1–52.

Passik SD, Kirsh KL, Whitcomb L, Portenoy RK, Katz NP, Kleinman L, Dodd SL, Schein JR. 2004. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. *Clinical Therapeutics* 26:552–561 DOI 10.1016/S0149-2918(04)90057-4.

Portenoy RK. 2011. Treatment of cancer pain. *The Lancet* 377:2236–2247 DOI 10.1016/S0140-6736(11)60236-5.

Reid J, Nolan AM, Scott EM. 2018. Measuring pain in dogs and cats using structured behavioural observation. *Veterinary Journal* 236:72–79 DOI 10.1016/j.tvjl.2018.04.013.

Reid J, Scott EM, Calvo G, Nolan AM. 2017. Definitive Glasgow acute pain scale for cats: validation and intervention level. *Veterinary Record* 180:449 DOI 10.1136/vr.104208.

Rice ASC, Cimino-Brown D, Eisenach JC, Kontinen VK, Lacroix-Fralish ML, Machin I, Mogil JS, Stöhr T. 2008. Animal models and the prediction of efficacy in clinical trials of analgesic drugs: a critical appraisal and call for uniform reporting standards. *Pain* 139:243–247 DOI 10.1016/j.pain.2008.08.017.

Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F, ESMO Guidelines Working Group. 2012. Management of cancer pain: ESMO clinical practice guidelines. *Annals of Oncology* 23(Suppl 7):vii139–51 DOI 10.1093/annonc/mds233.

Robertson SA, Lascelles BDX, Taylor PM, Sear JW. 2005. PK-PD modeling of buprenorphine in cats: intravenous and oral transmucosal administration. *Journal of Veterinary Pharmacology and Therapeutics* 28:453–460 DOI 10.1111/j.1365-2885.2005.00677.x.

Stathopoulou TR, Kouki M, Pypendop BH, Johnston A, Papadimitriou S, Pelligand L. 2018. Evaluation of analgesic effect and absorption of buprenorphine after buccal administration in cats with oral disease. *Journal of Feline Medicine and Surgery* 20:704–710 DOI 10.1177/1098612X17727234.

Steagall PVM, Taylor PM, Rodrigues LCC, Ferreira TH, Minto BW, Aguiar AJA. 2009. Analgesia for cats after ovariohysterectomy with either buprenorphine or carprofen alone or in combination. *Veterinary Record* 164:359–363 DOI 10.1136/vr.164.12.359.

Streiner DL, Cairney J. 2007. What’s under the ROC? An introduction to receiver operating characteristics curves. *Canadian Journal of Psychiatry* 52:121–128 DOI 10.1177/070674370705200210.

Streiner DL, Norman GR. 2008. Health Measurement Scales: a practical guide to their development and use. DOI 10.1093/acprof:oso/9780199231881.001.0001.

Taber KS. 2018. The use of Cronbach’s α when developing and reporting research instruments in science education. *Research in Science Education* 48:1273–1296 DOI 10.1007/s11165-016-9602-2.

Terrell JE, Ronis DL, Fowler KE, Bradford CR, Chepeha DB, Prince ME, Teknos TN, Wolf GT, Duffy SA. 2004. Clinical predictors of quality of life in patients with head and neck cancer. *Archives of Otolaryngology - Head and Neck Surgery* 130:401–408 DOI 10.1001/archotol.130.4.401.
Vardeh D, Naranjo JF. 2017. Peripheral and central sensitization. *Pain Medicine: An Essential Review* 15–17.

Walker HK. 1990. Cranial nerve V: the trigeminal nerve. In: *Clinical methods: the history, physical, and laboratory examinations*.

Woolf CJ. 2011. Central sensitization: implications for the diagnosis and treatment of pain. *Pain* 152(3 Suppl):S2–S15 DOI 10.1016/j.pain.2010.09.030.

Yazbek KVB, Fantoni DT. 2005. Validity of a health-related quality-of-life scale for dogs with signs of pain secondary to cancer. *Journal of the American Veterinary Medical Association* 226:1354–1358 DOI 10.2460/javma.2005.226.1354.

Ye Y, Bernabé DG, Salvo E, Viet CT, Ono K, Dolan JC, Janal M, Aouizerat BE, Miaskowski C, Schmidt BL. 2017. Alterations in opioid inhibition cause widespread nociception but do not affect anxiety-like behavior in oral cancer mice. *Neuroscience* 363:50–61 DOI 10.1016/j.neuroscience.2017.06.038.

Zaslansky R, Yarnitsky D. 1998. Clinical applications of quantitative sensory testing (QST). *Journal of the Neurological Sciences* 153:215–238 DOI 10.1016/S0022-510X(97)00293-1.

Zwakhalen SMG, Van Dongen KAJ, Hamers JPH, Abu-Saad HH. 2004. Pain assessment in intellectually disabled people: Non-verbal indicators. *Journal of Advanced Nursing* 45:236–245 DOI 10.1046/j.1365-2648.2003.02884.x.